U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07229157) titled 'Effect of Maridebart Cafraglutide on the Heart's Electrical Activity' on Nov. 13.
Brief Summary: The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Study Start Date: Nov. 18
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: Maridebart Cafraglutide
Participants will receive maridebart cafraglutide SC.
DRUG: Moxifloxacin
Participants will receive moxifloxacin orally.
DRUG: Placebo f...